Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

6.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.5K
Preventive Healthcare Services01:30

Preventive Healthcare Services

2.4K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

891
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
891
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.

JACC. Heart failure·2021
Same author

Impact of Geographic Region on the COMMANDER-HF Trial.

JACC. Heart failure·2021
Same author

The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure.

Journal of cardiac failure·2021
Same author

Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus.

Cardiovascular endocrinology & metabolism·2020
Same author

Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF.

European journal of heart failure·2020
Same author

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.

European heart journal·2020

Related Experiment Video

Updated: May 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Is aspirin useful in primary prevention?

John G F Cleland1

  • 1Imperial College London (Royal Brompton & Harefield Hospitals), London, UK and Department of Cardiology, Castle Hill Hospital, Hull and York Medical School, University of Hull, Kingston-upon-Hull HU6 5JQ, UK.

European Heart Journal
|August 3, 2013
PubMed
Summary

Current evidence suggests aspirin is not effective for primary cardiovascular prevention. Long-term aspirin use, even in patients with existing cardiovascular disease, lacks proven benefits and carries significant bleeding risks.

Keywords:
AspirinPrimary prevention

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

9.7K

Related Experiment Videos

Last Updated: May 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

9.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Aspirin is widely believed to prevent cardiovascular events by inhibiting thrombus formation.
  • However, alternative mechanisms of plaque instability, such as hemorrhage from vasa vasorum, are not addressed by aspirin.
  • Existing evidence on aspirin's benefits is questioned due to potential biases in meta-analyses.

Purpose of the Study:

  • To critically evaluate the evidence for aspirin's efficacy in cardiovascular disease prevention.
  • To assess the risks associated with long-term aspirin use.
  • To examine the reliability of current meta-analyses and clinical trial data regarding aspirin.

Main Methods:

  • Review and critical analysis of existing clinical trial data and meta-analyses on aspirin's cardiovascular effects.
  • Examination of theoretical mechanisms for aspirin's action versus observed clinical outcomes.
  • Assessment of potential biases in meta-analytic studies.

Main Results:

  • No convincing evidence supports aspirin for primary cardiovascular event prevention.
  • Long-term aspirin use, even in patients with known cardiovascular disease, is not supported by current data.
  • Aspirin is associated with serious risks, including gastrointestinal and intracranial bleeding.
  • Low-dose aspirin (50-100 mg/day) lacks demonstrated benefit in common clinical settings.
  • Potential for aspirin to interfere with beneficial cardiovascular drugs, like ACE inhibitors.
  • Evidence for cancer reduction is old and not applicable to current dosing strategies.

Conclusions:

  • The purported benefits of aspirin in cardiovascular prevention are not substantiated by reliable evidence.
  • The risks of serious bleeding associated with aspirin outweigh any potential benefits in most clinical scenarios.
  • Current low-dose aspirin regimens lack proven efficacy for cardiovascular disease prevention or other common clinical indications.